Cagrilintide is a longacting acylated analogue of the pancreatic hormone amylin, designed for onceweekly subcutaneous administration [1]
However the impact of the associated conformational rearrangements of amino acid residues on protein functions, ligand-bindings, and allosteric communications still remains poorly understood 1,2,3
Toxicol Pathol 2002
It supports Th1/Th2 balance, enhances T cell function and is anti-inflammatory
The challenge is distinguishing whats "normal" lean mass loss from dangerous, long-term bone thinning
Bowel Changes Reported in Clinical Trials Phase 2 trial data show nausea, vomiting, diarrhoea, and constipation are the most common GI side effects of retatrutide, with incidence increasing at higher doses